Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
Nicolás Roche, Megan Crichton, Pieter Goeminne, Bin Cao, Marc Humbert, Michal Shteinberg, Κατερίνα Αντωνίου, Charlotte Suppli Ulrik, Helen Parks, Chen Wang, Thomas Vandendriessche, Jieming Qu, Daiana Stolz, Christopher E. Brightling, Tobias Welte, Stefano Aliberti, Anita K. Simonds, Thomy Tonia, James D. Chalmers
Abstract
Since the identification of SARS-CoV2 at the end of 2019, the COVID-19 pandemic has affected more than 410 million people worldwide and killed almost 6 million [1, 2]. The predecessors of COVID-19 ( i.e. , SARS for severe acute respiratory syndrome and MERS for Middle-East respiratory syndrom) had been relatively self-limiting, preventing clinicians and researchers from establishing evidence-based specific therapeutic strategies [3]. Conversely, COVID-19 rapidly proved to be extremely fast spreading, which led stakeholders to encourage, guide, build or fund multidirectional therapeutic research strategies based on both repurposing and development of new agents [4–8]. The authors wish to thank Kristel Paque and Krizia Tuand, the biomedical reference librarians of the KU Leuven Libraries – 2Bergen – learning Centre Désiré Collen (Leuven, Belgium), for their help in conducting the systematic literature search.